The NIH has completed the high-throughput screening program. Working with a chemical library of more than 350,000 compounds, the NIH screened each compound at approximately 7 different dosage levels—resulting in more than 2 million unique screens.
Out of the 4000 FDA approved drugs, 10 "hits" or candidate medicines were found. At this point in time, we are not able to divulge the names of these compounds.
Out of the non-FDA approved drugs, 800 "hits" were discovered.
These 800 hits proved to reduce the amount of PMP22 in the cells, without causing any damage to the cells.
A second cell assay, created by John Svaren, is being sent to the NIH this week. The 810 hits discovered from the initial screening will be tested on Svaren's new assay over the summer and the final results should be released by the end of August.
At this point, we will know more about when the animal model testing will occur.
We are extremely excited about the progress made by the scientists involved in the STAR program. Never before has such a large portfolio of over 800 compounds been tested on a cell line in this fashion.